Fig. 6.

IL-12 conjugation improves the efficacy of CAR-T therapy. A, Bioluminescence image showing tumor burden in Raji xenograft model (n=5). B, Quantification of bioluminescent signal, and (C) mouse survival data for Raji xenograft model (n = 5, Mantel–Cox test). D, Number of anti-CD19 CAR-T cells per 1 mL of blood over time (n = 5). Animals were untreated (“tumor only;” light gray), treated with metabolically labeled T cells without CAR vector expression (“NP T cells;” dark orange), treated with metabolically labeled and IL-12-conjugated T cells without CAR vector expression (“NP T cells + conjugated IL-12;” brown), treated with CAR-T cells without labeling but without IL-12 conjugation (“CAR-T;” dark gray), treated with CAR-T cells metabolically labeled and transiently exposed to non-DBCO-conjugated IL-12 prior to transfer (“NP + transient IL-12;” purple), treated with CAR-T cells that were labeled and transferred with the same quantity of soluble IL-12 (not DBCO conjugated) as was conjugated to CAR-T cells (“NP + continuous IL-12;” blue), or treated with CAR-T cells that were metabolically labeled and then conjugated with IL-12 prior to transfer (“NP + conjugated IL-12;” green).